+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID06582875

Study of Glucagon-Like Peptide-1 Receptor Agonist Treatment to Slow Kidney Growth in Adults With Autosomal Dominant Polycystic Kidney Disease and Obesity

Led by University of Colorado, Denver · Updated on 2025-05-06

126

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effect of a glucagon-like peptide 1 receptor agonist GLP-1RA, a medication approved for weight management that also improves glucose and insulin response, on slowing kidney growth in adults with autosomal dominant polycystic kidney disease ADPKD who are overweight or obese. This phase II, randomized, placebo-controlled, double-blind clinical trial aims to determine if one year of treatment can slow kidney growth, as well as assess changes in abdominal fat and kidney metabolism using advanced imaging techniques. The study also collects blood and urine samples to explore biological changes linked to treatment benefits while monitoring safety and tolerability. Participants will receive either tirzepatide, a GLP-1RA drug, or a placebo. The dosing starts at 2.5 mg once weekly and escalates to 5 mg once weekly after 4 weeks, maintaining the target dose for 10 months. Dose adjustments are allowed to manage side effects, with a minimum tolerated dose of 2.5 mg per week required to continue. Both study groups follow the same dose-escalation regimen, and all dose changes are recorded. During the 12-month study, participants undergo assessments at baseline, 6 months, and 12 months including magnetic resonance imaging to measure kidney volume and abdominal fat, blood tests for inflammation and metabolism markers, and urine tests. Researchers monitor kidney growth as the primary outcome and track secondary measures such as body weight, insulin resistance, and kidney oxygen consumption. Safety and tolerability are carefully followed throughout the study period, with total participation lasting one year.

CONDITIONS

Brief Title

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Research Team

K

Kristen Nowak, PhD, MPH

D

Diana George

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here